| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
87,040,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company. Co. is engaged in developing and commercializing targeted therapies for patients with genomically-defined cancers. Co.'s main product candidate, DAY101 (tovorafenib), is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor. Co.'s second product candidate, pimasertib, is an oral, highly-selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a well-characterized key signaling node in the RAS/mitogen-activated protein kinase pathway.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
2,244,684 |
4,978,018 |
| Total Buy Value |
$0 |
$0 |
$24,978,318 |
$65,978,328 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
4 |
7 |
| Total Shares Sold |
225,453 |
235,538 |
246,104 |
4,525,329 |
| Total Sell Value |
$3,837,225 |
$3,955,119 |
$4,100,690 |
$62,122,635 |
| Total People Sold |
4 |
4 |
4 |
8 |
| Total Sell Transactions |
14 |
18 |
25 |
103 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bender Jeremy |
Chief Executive Officer |
• • – |
2023-03-07 |
4 |
AS |
$20.01 |
$250,114 |
D/D |
(12,500) |
1,174,276 |
|
- |
|
| Papanek Julie |
Director |
– • – |
2023-03-01 |
4 |
AS |
$18.61 |
$465,303 |
I/I |
(25,000) |
330,000 |
|
- |
|
| York Charles N Ii |
COO, CFO and Secretary |
• – – |
2023-02-17 |
4 |
AS |
$20.03 |
$187,790 |
D/D |
(9,377) |
262,128 |
|
- |
|
| Blackman Samuel C. |
Chief Medical Officer |
• – – |
2023-02-16 |
4 |
S |
$19.57 |
$13,192 |
D/D |
(674) |
1,243,660 |
|
- |
|
| York Charles N Ii |
COO, CFO and Secretary |
• – – |
2023-02-16 |
4 |
S |
$19.57 |
$18,203 |
D/D |
(930) |
271,505 |
|
- |
|
| Bender Jeremy |
Chief Executive Officer |
• • – |
2023-02-16 |
4 |
S |
$19.57 |
$59,150 |
D/D |
(3,022) |
1,186,776 |
|
- |
|
| Blackman Samuel C. |
Chief Medical Officer |
• – – |
2023-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,624 |
1,244,334 |
|
- |
|
| York Charles N Ii |
COO, CFO and Secretary |
• – – |
2023-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,625 |
272,435 |
|
- |
|
| Bender Jeremy |
Chief Executive Officer |
• • – |
2023-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,312 |
1,189,798 |
|
- |
|
| Blackman Samuel C. |
Chief Medical Officer |
• – – |
2023-02-10 |
4 |
AS |
$20.07 |
$200,659 |
D/D |
(10,000) |
1,241,710 |
|
- |
|
| Papanek Julie |
Director |
– • – |
2023-02-01 |
4 |
AS |
$21.21 |
$530,794 |
I/I |
(25,000) |
355,000 |
|
- |
|
| Bender Jeremy |
Chief Executive Officer |
• • – |
2023-01-23 |
4 |
AS |
$22.00 |
$274,988 |
D/D |
(12,500) |
1,181,486 |
|
- |
|
| York Charles N Ii |
COO, CFO and Secretary |
• – – |
2023-01-20 |
4 |
AS |
$22.75 |
$227,523 |
D/D |
(10,000) |
268,810 |
|
- |
|
| Blackman Samuel C. |
Chief Medical Officer |
• – – |
2023-01-10 |
4 |
AS |
$22.75 |
$228,644 |
D/D |
(10,000) |
1,250,148 |
|
- |
|
| Papanek Julie |
Director |
– • – |
2023-01-03 |
4 |
AS |
$20.36 |
$516,147 |
I/I |
(25,000) |
380,000 |
|
- |
|
| Bender Jeremy |
Chief Executive Officer |
• • – |
2022-12-21 |
4 |
AS |
$20.32 |
$253,969 |
D/D |
(12,500) |
1,192,424 |
|
- |
|
| York Charles N Ii |
COO, CFO and Secretary |
• – – |
2022-12-20 |
4 |
AS |
$20.07 |
$200,650 |
D/D |
(10,000) |
276,497 |
|
- |
|
| Atlas Venture Fund Xi, L.p. |
10% Owner |
– – • |
2022-12-12 |
4 |
AS |
$0.00 |
$0 |
D/D |
(600,854) |
6,008,534 |
|
- |
|
| Papanek Julie |
Director |
– • – |
2022-12-08 |
4 |
AS |
$22.08 |
$96,210 |
I/I |
(4,358) |
405,000 |
|
- |
|
| Papanek Julie |
Director |
– • – |
2022-12-02 |
4 |
AS |
$21.55 |
$107,726 |
I/I |
(5,000) |
409,358 |
|
- |
|
| Papanek Julie |
Director |
– • – |
2022-12-01 |
4 |
AS |
$21.72 |
$108,754 |
I/I |
(5,000) |
414,358 |
|
- |
|
| Blackman Samuel C. |
Chief Medical Officer |
• – – |
2022-12-01 |
4 |
AS |
$21.38 |
$214,530 |
D/D |
(10,000) |
1,260,148 |
|
- |
|
| Bender Jeremy |
Chief Executive Officer |
• • – |
2022-11-21 |
4 |
AS |
$20.74 |
$259,479 |
D/D |
(12,500) |
1,204,924 |
|
- |
|
| York Charles N Ii |
COO, CFO and Secretary |
• – – |
2022-11-21 |
4 |
AS |
$20.74 |
$207,570 |
D/D |
(10,000) |
286,497 |
|
- |
|
| York Charles N Ii |
COO, CFO and Secretary |
• – – |
2022-11-16 |
4 |
S |
$21.46 |
$9,228 |
D/D |
(430) |
296,497 |
|
- |
|
174 Records found
|
|
Page 3 of 7 |
|
|
